Search Results
Aug 25, 2025, 03:26 ET Leqembi® (lecanemab) launched in the EU today
doi:10.1038/s41467-021-23507-z. vi Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. vii Froelich L., et al. Lecanemab for treatment
More news about: BioArctic
Aug 22, 2025, 09:00 ET Diagnóstico precoce e tratamento adequado podem evitar 1,6 milhão de mortes por doença renal crônica e reduzir pela metade a necessidade de diálise no Brasil1
bibliográfica: Tangri N, et al. Impact of improved diagnosis and treatment on holistic chronic kidney disease burden. Kidney Int Rep. 2025. In press. Journal Pre-proof. doi:10.1016/j.ekir.2025.05.039. Disponível em:
More news about: AstraZeneca
Aug 15, 2025, 19:54 ET Rocket Companies Announces Early Tender Results of Exchange Offers and Consent Solicitations for Any and All of Nationstar Mortgage Holdings Inc.'s 6.500% Senior Notes Due 2029 and 7.125% Senior Notes Due 2032 and Receipt of Requisite Consents
(Banks and Brokers). None of Rocket Companies, its board of directors, Mr. Cooper, Nationstar, the Guarantors, the Dealer Managers (as defined int the Offering Memorandum and Consent Solicitation Statement), the Depositary and Information Agent, the Trustee under the Indentures, or any of their
More news about: Rocket Companies, Inc.
Aug 15, 2025, 17:30 ET Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver Int. 2023;43(5):964-974. doi:10.1111/liv.15555Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic
More news about: NOVO NORDISK INC.
Aug 13, 2025, 14:21 ET OncoBeta reports 12-Month Results from International Phase IV Study for Non-Melanoma Skin Cancer
Nuc Med. 2023;48(10):869–876.Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;48(5):1511–1521.Cipriani C, et al. Int J Nucl Med. 2017;114–112.Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.Contact:Jane
More news about: OncoBeta GmbH
Aug 12, 2025, 07:47 ET Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
fund our current operating plan into the second half of 2026." About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Aug 12, 2025, 07:30 ET "Prime Time," a Branded Peyronie's Disease Commercial for XIAFLEX® (collagenase clostridium histolyticum)
analysis of claims filed September 2022 through August 2023. References Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.DiBenedetti DB, Nguyen
More news about: Endo USA, Inc.
Aug 07, 2025, 16:06 ET Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
equivalents totaled $2.2 million. About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Aug 06, 2025, 08:52 ET First Patient Randomised in Samson Clinical Phase III Sublingual Minoxidil Trial for Male Pattern Hair Loss (Androgenetic Alopecia)
1 Sinclair, R. D., Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol, 2018; 57: 104–109. doi:10.1111/ijd.13838 Media Contact:Ellen Williamson+61
More news about: Samson Clinical
Aug 05, 2025, 00:37 ET Le test MosaiQ AiPlex® Vasculitis est désormais disponible pour une utilisation clinique dans l'Union européenne et dans d'autres pays acceptant le marquage CE
Criteria.Ann Rheum Dis. 2022;81(3):309-314. 5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. 6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
More news about: AliveDx
Aug 04, 2025, 12:36 ET El ensayo de vasculitis MosaiQ AiPlex® disponible para uso clínico en la Unión Europea
Criteria.Ann Rheum Dis. 2022;81(3):309-314. 5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. 6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
More news about: AliveDx
Aug 04, 2025, 09:18 ET MosaiQ AiPlex® Vaskulitis-Assay jetzt für den klinischen Einsatz in der Europäischen Union und anderen Ländern, die das CE-Zeichen akzeptieren, verfügbar
Criteria.Ann Rheum Dis. 2022;81(3):309-314.5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology
More news about: AliveDx
Aug 04, 2025, 09:00 ET MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European Union and other CE mark accepting countries
Criteria.Ann Rheum Dis. 2022;81(3):309-314. 5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. 6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
More news about: AliveDx
Aug 04, 2025, 09:00 ET MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European Union and other CE mark accepting countries
Criteria.Ann Rheum Dis. 2022;81(3):309-314. 5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. 6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
More news about: AliveDx
Aug 04, 2025, 07:47 ET Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
with minimal disruption to the market and typically lower costs. About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Aug 01, 2025, 08:00 ET AUSTIN BUTLER FRONTS NEW YSL BEAUTY MYSLF ABSOLU CAMPAIGN
https://www.yslbeauty.com/int/ourika-community-gardens.html
More news about: YSL Beauté
Jul 31, 2025, 07:01 ET CW Bancorp Reports Second Quarter 2025 Financial Results
Int Bearing Due from Banks & FFS $
More news about: CW Bancorp
Jul 30, 2025, 11:00 ET Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 30, 2025, 09:00 ET New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 30, 2025, 08:07 ET Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 28, 2025, 16:30 ET LINKBANCORP, Inc. Announces Strong Second Quarter 2025 Earnings and Declares Dividend
Yield/Rate Int. Earn. Cash
More news about: LINKBANCORP, Inc.
Jul 25, 2025, 04:22 ET 페레로 그룹, 2024년 지속 가능성 보고서 발표 - 글로벌 위기 속에서도 확고한 의지, 혁신, 영향력 입증
https://www.ferrero.com/int/en/people-planet/sustainability-reporting 연락처: [email protected]
More news about: The Ferrero Group
Jul 24, 2025, 17:00 ET Primis Financial Corp. Reports Earnings per Share for the Second Quarter of 2025
2Q25 Int. Inc. Recog. – Consumer Prog.
More news about: Primis Financial Corp.
Jul 23, 2025, 09:00 ET First Community Corporation Announces Record Earnings and Increased Cash Dividend
Int bearing deposits in other banks 155,861
More news about: First Community Corporation
Jul 22, 2025, 03:03 ET 中国青島：魅力で称賛を勝ち取り、開放して協力を促進
世界市長対話・青島イベント開催 青島（中国）、2025年7月22日 /PRNewswire/ -- Chengda Int. Mediaより：19日午前、「世界市長対話・青島」イベントが中国の青島で開催された。青島市の任剛市長は、日本の下関市、韓国の大邱広域市、ドイツのレーゲンスブルク市など多くの友好都市の市長や市長代表と、海洋観光の発展、歴史的都市の活性化、人文交流の緊密化などをめぐって交流を展開した。
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.